{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:54:03Z","timestamp":1781589243854,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy with checkpoint inhibitor (ICI) has revolutionized the treatment of cancer including squamous cell carcinoma. Nevertheless, there is an unmet need to gain a better understanding of the effect of these therapies on pregnancy and fertility. Treatment with anti-PD-1 therapy decreases fetal\u2013maternal tolerance and increases the risk of pregnancy loss in animal studies. However, few data are currently available in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of conception and pregnancy, with successful maternal and fetal outcomes, in a young woman with metastatic squamous cell carcinoma originated from the palatin tonsil. She was 17-year-old at the diagnosis. After surgical removal of the primary tumor, she received adjuvant radiotherapy. Four years later she underwent surgery for a lung relapse and adjuvant chemotherapy. Three years later the patient experienced a pulmonary and mediastinal relapse. Immunotherapy with nivolumab was promptly started with a slow reduction of the disease until a near radiological complete response with a unique residual lung subpleural nodulation. Surgical romoval confirmed the residual disease of squamous cell carcinoma. Patient re-started immunotherapy with nivolumab but after 2 months, she was found to be 4 weeks pregnant. Treatment was stopped and, since the patient expressed her desire to carry her pregnancy to term, she was referred to gynecological and psychological support. She had an uneventful pregnancy, followed by spontaneous vaginal delivery. The baby was healthy and exhibited normal development. Furthermore, the patient breastfed until the sixth month without any adverse effects on the child growth. In November 2025, after 32 months of disease-free survival, the patient developed a new lung recurrence, presenting as a single 4-cm diameter lesion in the right lower lobe. In January 2026, she underwent surgical resection of the lesion and histology was consistent with the diagnosis of metastatic disease. Currently, in the absence of detectable disease, the patient continues active follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our case provides evidence that pregnancy and normal fetal development may occur after early exposure to nivolumab, Nevertheless, the impact of treatment interruption and pregnancy on disease recurrence remains an unresolved question.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1826390","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:37:45Z","timestamp":1781588265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Long-term maternal and neonatal outcomes after nivolumab therapy in metastatic tonsillar sarcomatoid squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Elisabetta","family":"Guida","sequence":"first","affiliation":[{"name":"Biostatistics and Bioinformatics Laboratory, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Apollonio","sequence":"additional","affiliation":[{"name":"Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bungaro","sequence":"additional","affiliation":[{"name":"Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Mele","sequence":"additional","affiliation":[{"name":"Pathology Department, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[{"name":"Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cell Oncol (Dordr)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1596583","article-title":"Advances and challenges in immunotherapy in head and neck cancer","volume":"16","author":"Aboaid","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/ppo.0000000000000296","article-title":"Toxicities associated with PD-1\/PD-L1 blockade","volume":"24","author":"Wang","year":"2018","journal-title":"Cancer J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114010","article-title":"Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors","volume":"202","author":"Helgadottir","year":"2024","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30059-7","article-title":"Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients","volume":"19","author":"de Haan","year":"2018","journal-title":"Lancet Oncol"},{"key":"B7","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s110lbl.pdf\n          \n          2026"},{"key":"B8","article-title":"NCCN clinical practice guidelines in oncology: melanoma version 2","volume-title":"NCCN clinical practice guidelines in oncology: melanoma","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0837","article-title":"It is time to talk about fertility and immunotherapy","volume":"25","author":"Duma","year":"2020","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100276","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2023.103799","article-title":"Immune checkpoint inhibitors and reproductive failures","volume":"156","author":"Chen","year":"2023","journal-title":"J Reprod Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050019","article-title":"A critical role for the programmed death ligand 1 in fetomaternal tolerance","volume":"202","author":"Guleria","year":"2005","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21176","article-title":"An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2308135","article-title":"Severe immune-related enteritis after in utero exposure to pembrolizumab","volume":"389","author":"Baarslag","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5625","article-title":"Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns","volume":"7","author":"Gougis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948382","article-title":"Immune checkpoint molecules in pregnancy: Focus on regulatory T cells","volume":"50","author":"Zhang","year":"2020","journal-title":"Eur J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(04)01466-4","article-title":"Use of chemotherapy during human pregnancy","volume":"5","author":"Cardonick","year":"2004","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/humrep\/deae254","article-title":"Immune system regulation of physiological and pathological aspects of the ovarian follicle pool throughout the female reproductive lifespan","volume":"40","author":"Cacciottola","year":"2025","journal-title":"Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1641","article-title":"Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma","volume":"6","author":"Scovell","year":"2020","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41419-018-1251-0","article-title":"Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00525-8","article-title":"Immunotherapy for cancer treatment during pregnancy","volume":"22","author":"Borgers","year":"2021","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.22541\/au.172320180.09605335\/v1","article-title":"Female oncofertility and immune checkpoint blockade in melanoma: Where are we today","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou","year":"2021","journal-title":"ESMO Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102356","article-title":"Systematic review of fetal and placental metastases among pregnant patients with cancer","volume":"104","author":"Khazzaka","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0110","article-title":"Monoclonal antibodies during breastfeeding","volume":"16","author":"Anderson","year":"2021","journal-title":"Breastfeed Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.04.14","article-title":"The role of pulmonary metastasectomy for pulmonary metastasis from head and neck cancer","volume":"13","author":"Shiono","year":"2021","journal-title":"J Thorac Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202406.1840.v1","article-title":"Progression-free survival and treatment-free interval in head and neck cancer with long-term response to nivolumab: Timing of active discontinuation","volume":"16","author":"Matsuo","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826390\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:37:49Z","timestamp":1781588269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826390\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1826390"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1826390","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1826390"}}